What infection surveillance protocol should be used during induction therapy with immunosuppressive agents?

Infection Surveillance During Induction Immunosuppressive Therapy

Universal screening for hepatitis B (HBsAg, anti-HBs, anti-HBc) and tuberculosis (preferably with interferon-gamma release assay) should be performed before initiating immunosuppressive therapy, followed by risk-stratified monitoring protocols based on the specific immunosuppressive regimen used. 1, 2, 3

Pre-Treatment Screening (Mandatory)

All patients must undergo baseline screening before starting immunosuppression:

• Hepatitis B markers: HBsAg, anti-HBs, and anti-HBc 1, 2

  • If HBsAg positive or anti-HBc positive: obtain HBV DNA quantification
  • This screening is critical as HBV reactivation can occur in 15-50% of HBsAg-positive patients without prophylaxis 2

• Tuberculosis screening: Interferon-gamma release assay (IGRA) preferred over tuberculin skin test 4, 3

  • IGRA has no cross-reactivity with BCG vaccination and is more specific for recent infection
  • Particularly important before anti-TNF therapy and other high-risk immunosuppression

• Hepatitis C: Anti-HCV antibody testing; if positive, perform HCV RNA 4, 3

• Varicella zoster virus: Assess immunity status 3

Risk-Stratified Monitoring Protocols

High-Risk Immunosuppression

B-cell depleting agents (rituximab, alemtuzumab), high-dose corticosteroids (>15-30 mg prednisone daily for >2-4 weeks), anthracyclines, allogeneic transplant

Monitoring frequency: Every 3 months during therapy 1

• HBsAg-positive patients on prophylaxis:

  • HBV DNA and ALT/AST every 3 months during therapy
  • Continue monitoring 3-6 months after stopping antivirals 1
  • For rituximab: extend monitoring up to 2 years post-treatment due to delayed reactivation risk 1

• HBsAg-negative/anti-HBc-positive patients:

  • Monitor HBsAg and HBV DNA every 3 months 1
  • For rituximab regimens: consider prophylactic antivirals rather than monitoring alone 1

Moderate-Risk Immunosuppression

Standard chemotherapy, conventional DMARDs, moderate-dose steroids

Monitoring frequency: Every 3 months 1

• HBV DNA and aminotransferases for HBsAg-positive patients
• HBsAg monitoring for anti-HBc-positive patients
• Initiate treatment promptly if HBV DNA becomes detectable

Low-Risk Immunosuppression

Low-dose steroids, single conventional synthetic DMARDs

Monitoring frequency: Every 3-6 months 1

• Less intensive surveillance acceptable
• Maintain clinical vigilance for signs of infection

Post-Treatment Surveillance

Critical monitoring period extends beyond therapy completion:

• Standard regimens: Continue monitoring for 6 months after last immunosuppressive dose 1

• Rituximab-containing regimens: Extend monitoring to 12-24 months post-treatment 1

  • HBV reactivation documented up to 2 years after rituximab discontinuation
  • Monitor HBV DNA (or HBsAg in anti-HBc-positive patients) throughout this period

• After stopping antiviral prophylaxis: Test HBV DNA and ALT/AST at 3-6 month intervals to detect late reactivation 1

Additional Surveillance Considerations

Pneumocystis jirovecii prophylaxis monitoring: 4, 3

• Consider prophylaxis when prednisone >15-30 mg daily for >2-4 weeks
• Monitor for respiratory symptoms and consider prophylaxis in high-risk scenarios

General infection surveillance: 5

• Complete blood count with differential at baseline, 4-8 weeks after starting, then every 3 months
• Comprehensive metabolic panel on same schedule
• Increased vigilance during first 30 days post-initiation and after rejection treatment 6

Common Pitfalls to Avoid

1. Failing to screen before therapy initiation - HBV reactivation can be fatal; screening must occur before first dose 2
2. Stopping monitoring too early with rituximab - reactivation risk persists 1-2 years post-treatment 1
3. Using monitoring instead of prophylaxis in high-risk HBsAg-positive patients - these patients require antiviral prophylaxis, not just monitoring 2, 7
4. Inadequate post-prophylaxis surveillance - reactivation can occur after stopping antivirals 1